Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Actinium Pharmaceuticals Inc (NY: ATNM )

7.785 USD -0.345 (-4.25%)
Streaming Delayed Price Updated: 11:13 AM EDT, Apr 12, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 240,734
Open 7.780
Bid (Size) 7.750 (10)
Ask (Size) 7.790 (4)
Prev. Close 8.130
Today's Range 7.650 - 8.040
52wk Range 4.710 - 19.47
Shares Outstanding 80,072,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Actinium to Participate in the Cell & Gene Meeting on the Mediterranean
- Actinium to highlight Iomab-ACT program for targeted conditioning for CAR-T, adoptive cell therapies, and gene therapies 
From PR Newswire
Actinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patients with R/R AML
- Proof-of-concept Phase 1 data expected in 2H:2021 will evaluate safety, response rates, MRD negativity and cytogenetic profiles 
From PR Newswire

Performance

YTD
-0.96%
-0.96%
1 Month
-15.20%
-15.20%
3 Month
-5.98%
-5.98%
6 Month
-25.72%
-25.72%
1 Year
+33.07%
+33.07%

More News

Read More
Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell Therapy
From PR Newswire
Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC
From PR Newswire
Actinium Announces Appointment of Mark Kubik, MBA as Chief Business Officer
From PR Newswire
Actinium Announces Participation in H.C. Wainwright Global Life Sciences Conference
From PR Newswire
Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual Meeting
From PR Newswire
Anthem, Inc. To Acquire myNEXUS, Home Health Benefits Manager
From Business Wire News Releases
Actinium Announces Participation in BIO CEO & Investor Digital Conference
From PR Newswire
Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference
From PR Newswire
Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.